N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
1. A method of preparing the metformin acetate of formula 1, which comprises reacting the metformin hydrochloride of formula 4 in alcohol with inorganic base to generate metformin free base; removing the resulting inorganic salt through filtering and concentrating process; and reacting the resultant with acetic acid as an organic acid in an organic solvent:
2. A method of preparing the metformin acetate of formula 1 in water as a solvent, which comprises reacting the metformin hydrochloride of formula 4 with acetic acid and inorganic base in an organic solvent in one reactor without special purifying process:
3. The method of preparing the metformin acetate of formula 1 according to claim 1 or 2 , wherein the inorganic base is sodium hydroxide or potassium hydroxide.
4. The method of preparing the metformin acetate of formula 1 according to claim 1 or 2 , wherein the molecular ratio of inorganic base reacting with 1 mole of the metformin hydrochloride is 1 to 2.
5. The method of preparing the metformin acetate of the formula 1 according to claim 1 , wherein the molecular ratio of acetic acid reacting with 1 mole of the metformin free base is 1 to 2.
6. A method of preparing the metformin acetate of formula 1, which comprises reacting the metformin hydrochloride of formula 4 with organic alkali in water, and then reacting the resultant with acetic acid as an organic acid without removing inorganic salt:
7. The method of preparing the metformin acetate of formula 1 according to claim 6 , wherein the organic alkali is sodium hydrogen carbonate, potassium carbonate, sodium acetate or sodium acetate trihydrate.
8. The method of preparing the metformin acetate of formula 1 according to claim 6 , wherein the molecular ratio of organic alkali reacting with 1 mole of the metformin hydrochloride is 1 to 2.
9. The method of preparing the metformin acetate of formula 1 according to any one of claims 1 , 2 and 6 , wherein the reaction is carried out in the temperature range of −10 to 50° C.
10. The method of preparing the metformin acetate of formula 1 according to claim 1 or 2 , wherein the organic solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, acetone and acetonitrile.
11. A method of treating diabetes mellitus or its complication, which comprises administrating to a patient a effective amount of a pharmaceutical composition containing the metformin acetate of formula 1 as an active ingredient:
12. The method of claim 11 , wherein the patient has metabolic syndromes.
13. The method of claim 11 , wherein the diabetes mellitus is type 2 diabetes mellitus.
14. The method of claim 11 , wherein the metformin acetate is orally administrated in amount of 50 to 3,000 mg per day.
15. The method of claim 11 , wherein the metformin acetate is anhydrous metformin acetate.
16. A method of treating glycosuria, hypertension, hyperlipidemia, fatty liver, or coronary heart diseases, which comprises administrating to a patient a effective amount of a pharmaceutical composition containing the metformin acetate of formula 1 as an active ingredient:
17. The method of claim 16 , wherein the metformin acetate is anhydrous metformin acetate.